Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBIT (2016 - 2025)

Rocket Pharmaceuticals' EBIT history spans 10 years, with the latest figure at -$44.0 million for Q4 2025.

  • For Q4 2025, EBIT rose 29.88% year-over-year to -$44.0 million; the TTM value through Dec 2025 reached -$231.7 million, up 15.17%, while the annual FY2025 figure was -$231.7 million, 15.17% up from the prior year.
  • EBIT for Q4 2025 was -$44.0 million at Rocket Pharmaceuticals, up from -$52.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$34.0 million in Q2 2021 and bottomed at -$73.7 million in Q2 2024.
  • The 5-year median for EBIT is -$62.4 million (2023), against an average of -$57.8 million.
  • The largest annual shift saw EBIT crashed 81.28% in 2021 before it rose 29.88% in 2025.
  • A 5-year view of EBIT shows it stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then grew by 8.4% to -$63.3 million in 2023, then increased by 0.92% to -$62.7 million in 2024, then grew by 29.88% to -$44.0 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's EBIT are -$44.0 million (Q4 2025), -$52.2 million (Q3 2025), and -$71.1 million (Q2 2025).